🇺🇸 FDA
Pipeline program

ATA3219

ATA3219-AEC-104

Phase 1 small_molecule terminated

Quick answer

ATA3219 for Lupus Nephritis is a Phase 1 program (small_molecule) at Atara Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Atara Biotherapeutics
Indication
Lupus Nephritis
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials